The publisher
About Tesamorelin Source
A primary-source reading of the published tesamorelin literature, set down in plain type — every figure traced to the study that measured it.
What this site is
Tesamorelin Source reads the peer-reviewed research literature on tesamorelin from the primary documents — the trials and monographs themselves — and sets each finding down in plain type. No clinic or pharmacy stands behind it; no one here sees patients, prescribes, or dispenses, and there is no counter and nothing to buy. The work is a reading of published science with every figure traced to source — it recounts what the studies measured, it does not diagnose, treat, or advise.
The word "source" in the name is editorial framing — a position we occupy relative to the literature, reading it straight and tracing every figure back to its study. It is not a claim that we supply, sell, or dispense tesamorelin or anything else. There is no storefront here and no counter. What we mean by "source" is the primary-document register: we go to the trials and the monographs themselves rather than to secondhand summaries, and we keep the page close to what those documents actually measured.
How we work
Every quantitative statement on this site — every percentage, dose, half-life, and effect size — is tied to a numbered citation that resolves on the references and citations page to a peer-reviewed study, an NIH monograph, or a published review. We lead with what was measured and attribute it to its source. Where the evidence is strong, we say so plainly; where it is limited to a specific population, we mark that boundary rather than smoothing it over.
The design reflects the editorial stance: a near-monochrome page, vast white space, and one number at a time. The intent is a sober reference plate, not a sales funnel.
What we are careful about
Tesamorelin is FDA-approved, but only to reduce excess abdominal fat in HIV-associated lipodystrophy; every other use is off-label, and we mark that line wherever it appears. We give no human dosing instructions and frame all dose information as what was administered in studies. We do not use brand names, and we do not name competitor products. And we are explicit that research-grade material supplied for laboratory use is not the approved finished drug product and is not approved for human self-administration.
We also try to be careful about emphasis, not just accuracy. Where a finding is robust — the visceral-fat reduction in HIV — we state it plainly. Where a secondary claim is unsettled, such as the mixed cognitive results, we say so rather than letting the stronger result lend it credibility. The goal is a record a reader can trust precisely because it marks its own limits. For the questions readers ask most, see the common questions about tesamorelin.